2nd Quarter - Report

TEVA PHARMACEUTICALS USA, INC. for TEVA PHARMACEUTICALS USA INC

Firm
Client
Income
—
Expenses
$580,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Trade (domestic/foreign) TRD

Foreign export restrictions pertaining to India and Italy

Foreign entity interest: Teva Pharmaceutical Industries, Ltd., as the indirect parent of Teva Pharmaceuticals USA Inc., has an interest in the issues listed.

LobbyistCovered position, as disclosed
MICHAEL BRZICA —
DOLLY A JUDGE —
COLMAN BRENDAN RAGAN —

Contacted: Health & Human Services, Dept of (HHS); State, Dept of (DOS); Executive Office of the President (EOP); Natl Security Council (NSC); HOUSE OF REPRESENTATIVES; SENATE; Food & Drug Administration (FDA); White House Office

Health Issues HCR

Legislation and proposals related to the COVID-19 crisis; HR 3199-Terminating the Extension of Rights Misappropriated Act of 2019; S.64-Preserve Access to Affordable Generic & Biosimilars Act; HR 1499-Protecting Consumer Access to Generic Drugs Act; HR 1344-Competitive Drugs Act of 2019; HR 938-Bringing Low Cost Options & Competition While Keeping Incentives for New Generics Act ("BLOCKING Act"); HR 1506-Fair & Immediate Release of Generic Drugs Act; HR 1520-Purple Book Continuity Act; HR 1503-Orange Book Transparency Act; S.344/HR 990-Hatch-Waxman Integrity Act; Stronger Patents Act; S.1895-Lower Health Care Costs Act; S. 2543-Prescription Drug Pricing Reduction Act; HR 3-Elijah E Cummings Lower Drug Costs Now Act; Administration review of drug pricing policies; Proposals to improve pharmaceutical supply-chain vlunterabilities; HR 4597-Acting to Cancel Copays & Ensure Substantial Savings for Biosimilars (ACCESS) Act; HR 4455-Bolstering Innovative Options to Save Immediately on Medicines (BIOSIMS) Act; HR 6179-Lowering Costs for Taxpayers & Medicare Seniors with Biosimilars; HR 4629-Star Ratings for Biosimilars Act.

Foreign entity interest: Teva Pharmaceutical Industries, Ltd., as the indirect parent of Teva Pharmaceuticals USA Inc., has an interest in the issues listed.

LobbyistCovered position, as disclosed
MICHAEL BRZICA —
DOLLY A JUDGE —
COLMAN BRENDAN RAGAN —

Contacted: HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); White House Office; SENATE; Natl Security Council (NSC); Health & Human Services, Dept of (HHS); Executive Office of the President (EOP); State, Dept of (DOS)

Bills named: H.R. 6179 (116th), H.R. 1520 (116th), H.R. 1503 (116th), H.R. 3199 (116th), H.R. 938 (116th), S. 1895 (116th), H.R. 4597 (116th), S. 64 (116th), H.R. 1499 (116th), H.R. 1344 (116th), S. 2543 (116th), H.R. 4629 (116th), S. 344 (116th), H.R. 4455 (116th), H.R. 1506 (116th), H.R. 3 (116th), H.R. 990 (116th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.